LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

Strona główna・Stock List・CytoSorbents Corp

CytoSorbents Corp

Closed

SectorHealthcare

0.45 2.27

Buy Sell

Overview

Share price change

24h

Current

Min

0.42

Max

0.46

Key metrics
By Trading Economics
Income	368K -5.1M
Sales	-370K 8.9M
EPS	-0.08
Profit margin	-57.863
Employees	129
EBITDA	648K -3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+63.04% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-11M 29M
Previous open	-1.82
Previous close	0.45

News Sentiment

By Acuity

46%

54%

140 / 344 Ranking in Healthcare

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 maj 2026, 16:52 UTC

Major News Events

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q Rev $1.76B >SQM

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q EPS $1.28 >SQM

26 maj 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q EPS $11.61 >WEBC

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q Sales $179.6M >WEBC

26 maj 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 maj 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 maj 2026, 20:58 UTC

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 maj 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 maj 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 maj 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 maj 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 maj 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 maj 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 maj 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 maj 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 maj 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 maj 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

26 maj 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 maj 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 maj 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

63.04% upside

12 Months Forecast

Average 0.75 USD 63.04%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Sentiment

By Acuity

140 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.